← Leaderboards
Brian N Finck
Washington University
$17,740,854
Attributed
$19,186,452
Total exposure
17
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,367,702 · 18
By mechanism
R01$14,292,684 · 5
R42$2,891,197 · 2
P30$1,985,683 · 2
S10$523,743 · 1
R56$305,000 · 1
K01$260,157 · 1
Top collaborators
- Timothy R Peterson4 shared
- Rolf F Kletzien3 shared
Most similar at Washington University
Same institution · by research overlap
- Angela Marie Hall$858,240
- David C Wright$49,928
Others in their field
Top investigators on “Obesity”
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
ObesityMetabolicDiabetes MellitusLipidsHepaticMitochondriaMetabolismMetabolic DiseasesMolecularInsulin ResistanceMediatingLiverDesignLinkHepatocyteMouse ModelTriglyceridesFatty LiverLiver DiseasesPlayFatty Acid Glycerol EstersProteinsPathway InteractionsGlucose
Grant awards (58)
Targeting hepatic stellate cell metabolism to treat steatotic liver disease$2,978,209
R01 · FY2025 · DK · contact PI
Washington University Nutrition Obesity Research Center$1,181,250
P30 · FY2025 · DK · contact PI
Covalent regulation of branched chain amino acid metabolism$461,782
R01 · FY2025 · DK · contact PI
Animal Model Research Core$160,726
P30 · FY2025 · DK · contact PI
Covalent regulation of branched chain amino acid metabolism$461,782
R01 · FY2024 · DK · contact PI
Targeting the mitochondrial pyruvate carrier to treat insulin resistance and nonalcoholic fatty liver disease$411,336
R01 · FY2024 · DK · contact PI
Animal Model Research Core$161,529
P30 · FY2024 · DK · contact PI
Targeting the mitochondrial pyruvate carrier to treat insulin resistance and nonalcoholic fatty liver disease$428,476
R01 · FY2023 · DK · contact PI
Animal Model Research Core$160,726
P30 · FY2023 · DK · contact PI
Phenomaster NG Mouse Metabolic Phenotyping System$523,743
S10 · FY2022 · OD · contact PI
Novel insulin-sensitizing NASH/diabetes drugs.$497,526
R42 · FY2022 · DK
Targeting the mitochondrial pyruvate carrier to treat insulin resistance and nonalcoholic fatty liver disease$428,476
R01 · FY2022 · DK · contact PI
Novel Aspects of Hepatic Mitochondrial Amino Acid Metabolism$381,250
R01 · FY2022 · DK · contact PI
Animal Model Research Core$160,726
P30 · FY2022 · DK · contact PI
Novel insulin-sensitizing NASH/diabetes drugs.$497,526
R42 · FY2021 · DK
Targeting the mitochondrial pyruvate carrier to treat insulin resistance and nonalcoholic fatty liver disease$428,476
R01 · FY2021 · DK · contact PI
Novel Aspects of Hepatic Mitochondrial Amino Acid Metabolism$381,250
R01 · FY2021 · DK · contact PI
Animal Model Research Core$160,726
P30 · FY2021 · DK · contact PI
Novel insulin-sensitizing NASH/diabetes drugs.$497,526
R42 · FY2020 · DK
Novel Aspects of Hepatic Mitochondrial Amino Acid Metabolism$381,250
R01 · FY2020 · DK · contact PI
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS$418,815
R01 · FY2019 · DK · contact PI
Novel Aspects of Hepatic Mitochondrial Amino Acid Metabolism$381,250
R01 · FY2019 · DK · contact PI
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS$364,006
R01 · FY2019 · DK · contact PI
Novel insulin-sensitizing NASH/diabetes drugs.$223,817
R42 · FY2019 · DK
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS$418,815
R01 · FY2018 · DK · contact PI
NOVEL ASPECTS OF HEPATIC MITOCHONDRIAL AMINO ACID METABOLISM$381,250
R01 · FY2018 · DK · contact PI
ROLE OF THE MONOACYLGLYCEROL ACYLTRANSFERASE PATHWAY IN ADIPOSE TISSUE TRIGLYCERIDE METABOLISM$305,000
R56 · FY2018 · DK · contact PI
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS$414,730
R01 · FY2017 · DK · contact PI
LIPIN 1 AND CARDIAC METABOLISM IN THE CONTEXT OF LIPID OVERLOAD$381,250
R01 · FY2017 · HL · contact PI
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS$414,925
R01 · FY2016 · DK · contact PI
LIPIN 1 AND CARDIAC METABOLISM IN THE CONTEXT OF LIPID OVERLOAD$381,250
R01 · FY2016 · HL · contact PI
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$330,600
R01 · FY2016 · DK · contact PI
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS$410,065
R01 · FY2015 · DK · contact PI
LIPIN 1 AND CARDIAC METABOLISM IN THE CONTEXT OF LIPID OVERLOAD$375,531
R01 · FY2015 · HL · contact PI
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$330,600
R01 · FY2015 · DK · contact PI
LIPIN 1 AND CARDIAC METABOLISM IN THE CONTEXT OF LIPID OVERLOAD$381,250
R01 · FY2014 · HL · contact PI
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$330,600
R01 · FY2014 · DK · contact PI
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$330,600
R01 · FY2013 · DK · contact PI
Evaluation of PPARgam-sparing TZDs for Treating Non-Alcoholic Fatty Liver Disease$560,998
R42 · FY2012 · AA
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$297,950
R01 · FY2012 · DK · contact PI
Evaluation of PPARgam-sparing TZDs for Treating Non-Alcoholic Fatty Liver Disease$50,000
R42 · FY2012 · AA
Evaluation of PPARgam-sparing TZDs for Treating Non-Alcoholic Fatty Liver Disease$563,804
R42 · FY2011 · AA
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$297,950
R01 · FY2011 · DK · contact PI
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$300,960
R01 · FY2010 · DK · contact PI
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$304,000
R01 · FY2009 · DK · contact PI
HEPATIC FLUXES IN PGC-1 ALPHA KO MICE$17,838
P41 · FY2009 · RR · contact PI
LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM$304,000
R01 · FY2008 · DK · contact PI
HEPATIC FLUXES IN PGC-1 ALPHA KO MICE$10,458
P41 · FY2008 · RR · contact PI
HEPATIC FLUXES IN PGC-1 ALPHA KO MICE$15,122
P41 · FY2007 · RR · contact PI
Regulation of glucose transporter expression by PPARa$88,493
K01 · FY2005 · DK
CARDIAC PHENOTYPE INDUCED BY PPAR OVEREXPRESSION MIMIC THAT OF DIABETES MELLITU$649
P41 · FY2005 · RR
PPAR MEDIATED LIPOTOXIC IN PATHOGENESIS OF DIABETIC CARDIOMYOPATHY: DIETARY FAT$649
P41 · FY2005 · RR
Regulation of glucose transporter expression by PPARa$86,701
K01 · FY2004 · DK
CARDIAC PHENOTYPE INDUCED BY PPAR OVEREXPRESSION MIMIC THAT OF DIABETES MELLITUS$804
P41 · FY2004 · RR
PPAR MEDIATED LIPOTOXIC IN PATHOGENESIS OF DIABETIC CARDIOMYOPATHY: DIETARY FAT$804
P41 · FY2004 · RR
Regulation of glucose transporter expression by PPARa$84,963
K01 · FY2003 · DK
Dysregulated fat utilization in diabetic cardiomyopathy$28,082
F32 · FY2002 · HL
Dysregulated fat utilization in diabetic cardiomyopathy$34,832
F32 · FY2001 · HL